Aquestive Therapeutics (AQST) Operating Leases (2020 - 2025)
Historic Operating Leases for Aquestive Therapeutics (AQST) over the last 6 years, with Q3 2025 value amounting to $5.1 million.
- Aquestive Therapeutics' Operating Leases fell 862.1% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 862.1%. This contributed to the annual value of $5.0 million for FY2024, which is 798.3% down from last year.
- Aquestive Therapeutics' Operating Leases amounted to $5.1 million in Q3 2025, which was down 862.1% from $5.2 million recorded in Q2 2025.
- Aquestive Therapeutics' Operating Leases' 5-year high stood at $6.0 million during Q1 2023, with a 5-year trough of $1.9 million in Q4 2021.
- In the last 5 years, Aquestive Therapeutics' Operating Leases had a median value of $5.1 million in 2025 and averaged $4.4 million.
- As far as peak fluctuations go, Aquestive Therapeutics' Operating Leases tumbled by 3162.33% in 2021, and later skyrocketed by 16880.15% in 2023.
- Aquestive Therapeutics' Operating Leases (Quarter) stood at $1.9 million in 2021, then soared by 161.31% to $5.1 million in 2022, then rose by 6.18% to $5.4 million in 2023, then decreased by 7.98% to $5.0 million in 2024, then increased by 2.84% to $5.1 million in 2025.
- Its Operating Leases stands at $5.1 million for Q3 2025, versus $5.2 million for Q2 2025 and $5.4 million for Q1 2025.